Close Menu

The $1,000 genome won't do any good for science if researchers can't interpret it, says Adina Mangubat, CEO of Spiral Genetics, in Xconomy. While industry has focused most of its time and energy to creating better ways to sequence a genome, it has "largely ignored the computational power required to extract and analyze the genomic data in a timeframe that keeps it relevant," Mangubat adds. And most labs aren't prepared for all that data.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.